European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics

by Marie Weil
December 21, 2021
A A
Share on LinkedinShare on Twitter
  • Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • Cladribine selectively targets B and T cells, which are key contributors to autoimmune diseases such as NMOSD and gMG
  • Focused expansion in neuroinflammatory diseases builds on existing neurology portfolio in Multiple Sclerosis (MS) 

Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Merck entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a Swiss-based biotech company focused on rare neuroinflammatory diseases.

“Cladribine has a unique mechanism of action which is relevant in antibody-mediated disease such as NMOSD and gMG. In exploratory studies, cladribine demonstrated promising results in these diseases. These data have prompted us to initiate further development with cladribine in gMG and NMOSD to potentially bring a new therapeutic option to patients and expand our portfolio in this area,” said Danny Bar-Zohar, MD, Head of Global Development for the biopharma business of Merck.

Cladribine is a well characterized molecule that has been extensively studied across MS and oncologic disorders and has shown promising results in exploratory studies in gMG and NMOSD. Merck plans to leverage its existing capabilities to further develop an oral cladribine product tailored specifically for these indications. The transaction is expected to be closed in early 2022 after satisfactory completion of customary closing conditions.

Generalized myasthenia gravis is a disease in which patients experience weakness in ocular, limb, and respiratory muscles and that has a significant impact on Quality of Life. It is estimated that 700,000 people around the world are living with gMG. NMOSD, also known as Devic´s disease, is an autoimmune disease, often misdiagnosed as MS due to similar symptoms. NMOSD is estimated to impact 200,000 people around the world.

Tags: < Invest

Related Industries

Health

Boehringer Ingelheim and Microsoft partner to drive patient-centric and AI-backed clinical development

October 23, 2026
Health

AstraZeneca announces new strategic collaboration with insitro to use advanced AI systems to develop transformative therapeutics for difficult to treat cardiometabolic diseases

October 16, 2026
Health

Boehringer Ingelheim investments into sustainability-related programs and health partnerships to reach EUR 500 million

September 30, 2026
Health

Philips-led projects win ITEA awards for advancing AI-enabled healthcare innovation

September 17, 2026
Health

Sanofi and Cheplapharm to create new strategic partnership in mature medicines

September 15, 2026
Health

Exor and Philips Extend Long-term Relationship Agreement

August 11, 2026

IHG Hotels & Resorts strengthens development focus in Greece & Cyprus with the appointment of Rozenn Lavaur Fournier as Director of Development

November 6, 2026

...

Boehringer Ingelheim and Microsoft partner to drive patient-centric and AI-backed clinical development

October 23, 2026

...

Blackstone Closes Fourth Institutional European Direct Lending Fund with €13 Billion in Investable Capital

November 5, 2026

...

Hilton and Scandic Sign New Nordics Strategic Agreement

October 20, 2026

...

ABN AMRO appoints Eric Jones as Head of Marketing & Digital

November 3, 2026

...

ABN AMRO and Rabobank complete transfer of Alfam

November 3, 2026

...

Aki Temmes appointed Chief Financial Officer of UPM

October 20, 2026

...

IHG Hotels & Resorts hits 1,000 open hotels in Europe

October 23, 2026

...

Sunil Pandiri is promoted to Chief Operating Officer at Voith Hydro

November 1, 2026

...

Deutsche Bank and DWS extend strategic partnerships with Zurich until 2042

October 27, 2026

...

European Business European Business European Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist